Is it safe to treat UTI symptoms at a pharmacy?

For straightforward uncomplicated UTI in a young woman with classic symptoms and no risk factors, pharmacist prescribing is unlikely to cause harm and may be a reasonable access option in many circumstances. The clinical concern is when the symptom picture is not straightforward — when there is also pelvic pain, fever, unusual discharge, or a recent new sexual partner, where the differential includes pelvic inflammatory disease, an STI, or another condition requiring different management. If any of those features are present, a GP assessment that can include examination and pathology is the appropriate pathway. The practical message: mention all your symptoms, not just the ones you came in for.

What does 'lacks robust clinical trial evidence' actually mean?

It means there are few or no randomised controlled trials directly comparing patient outcomes when the same condition is managed by a pharmacist versus a GP. This is not the same as evidence that pharmacist prescribing causes harm — it means the comparative evidence has not been rigorously tested in clinical trials. Many healthcare practices predate the RCT era and operate without that level of evidence; the question is whether a genuinely contested prescribing expansion warranted better evidence before rollout. That is the RACGP's argument.

Pharmacist prescribing is spreading. Where is the evidence?

What just happened

The RACGP called on the Pharmacy Guild and state governments to publicly release the evidence base supporting pharmacist prescribing, after the SAX Institute published a report finding that pharmacist prescribing for approximately 20 common conditions in Australia lacks robust clinical trial evidence.

Pharmacist prescribing — where a pharmacist can diagnose and prescribe for a set of defined conditions without a GP referral — is now available in all Australian states and territories, following staged rollouts since around 2023. The conditions covered include uncomplicated urinary tract infections, oral contraception continuation, ear infections, minor skin conditions, and several others.

RACGP President Dr Michael Wright cited missed diagnoses as the specific patient-safety concern: UTI symptoms in young women were described as a case where pharmacist prescribing may result in chlamydia, gonorrhoea, or pelvic inflammatory disease being missed, treated as uncomplicated UTI, and inadequately managed.

The Pharmacy Guild rejected the framing, arguing that pharmacist prescribing improves access to care for Australians who cannot readily access a GP, and that the evidence available supports the programme. The debate is active and unresolved.

The both-and

The access argument is real

Australia has a genuine general practice access problem. In many regional and rural communities, a same-day GP appointment is not available. In metropolitan areas with GP shortages, it may not be available either. Emergency departments increasingly absorb presentations that could be managed in general practice — at higher cost and with longer waits.

For someone with classic UTI symptoms at 6pm on a Friday, the realistic alternatives are often: pharmacy, emergency department, or suffer through to Monday. Pharmacist prescribing offers a third option that is more accessible, less costly, and for many straightforward presentations, clinically appropriate.

That is a legitimate argument and the access gap it addresses is real. RACGP newsGP has documented extensively how underserviced areas in Australia are increasingly relying on non-GP services to fill gaps that Medicare funding has not resolved.

Dismissing pharmacist prescribing on evidence grounds without acknowledging the access vacuum it is filling would be incomplete analysis. The counterfactual is not “everyone sees a GP” — in the real world, the counterfactual for many patients is “no professional assessment at all.”

The clinical concern about UTI is specific and worth examining

The UTI example is worth unpacking because it appears in the RACGP statement for a reason.

UTI is one of the commonest conditions women present with, and one of the commonest conditions where the clinical picture is not as straightforward as the presenting complaint. Dysuria, frequency, and urgency — the textbook UTI symptom cluster — are also consistent with chlamydia, gonorrhoea, pelvic inflammatory disease, interstitial cystitis, vulvodynia, and in some cases endometriosis affecting the bladder.

Chlamydia is particularly relevant here. It is the most commonly notified STI in Australia, disproportionately affects women under 30, and is frequently asymptomatic or low-symptom — exactly the presentation where a quick “sounds like a UTI, here’s some trimethoprim” response is plausible. Untreated chlamydia can progress to PID, with consequences including chronic pelvic pain and fertility problems.

The question is not whether pharmacists miss this diagnosis — GPs miss it too, sometimes in exactly the same way. The question is whether a clinical context that does not include access to full history, physical examination, or ability to order pathology has a structurally higher miss rate for this category of presentation. That is a legitimate research question, and the SAX Institute report appears to be arguing that robust evidence answering it does not yet exist.

The evidence question is more nuanced than either side is stating

“Lacks robust clinical trial evidence” does not mean “no evidence” or “evidence of harm.” It means there are few or no randomised controlled trials comparing patient outcomes between pharmacist-prescribed and GP-prescribed management for the same conditions.

This is not an unusual situation in healthcare. Many well-established clinical practices — including some that have been GP-delivered for decades — were not tested in RCTs before becoming standard. The argument for RCT evidence before expanding prescribing authority is reasonable, but it applies unevenly across the healthcare system.

What makes this case different is that it involves a contested expansion of prescribing authority into a new professional group, operating on a meaningful scale across the country. That is exactly the context where policy advocates for a robust evidence requirement. Whether that ship has sailed now that pharmacist prescribing is live in all states is a different question.

2 cents

The clinical point that is actually useful for you this week is about how to present at a pharmacist — or anywhere — when you have UTI-like symptoms.

The symptoms you go in with are not the only ones that matter. If you also have pelvic pain, fever, discharge, or have had a new sexual contact recently, those details change the clinical picture significantly. Mentioning them is not oversharing — it is the information that routes you to the right assessment.

This is not a statement that pharmacist prescribing is unsafe or that you should never use it. For straightforward presentations with classic symptoms and no additional features, it may be a genuinely useful access point. The clinical concern narrows to presentations with a richer differential than uncomplicated UTI — and knowing whether yours fits that category is part of the value of mentioning everything.

The broader policy question — whether pharmacist prescribing should have been tested more rigorously before national rollout — will continue to be debated. Watch for the evidence base to develop over the next few years as real-world outcome data accumulates.

Verdict: maybe — the access argument is real and the clinical concern is specific and plausible; the evidence will mature. In the meantime, give whoever you see the full clinical picture.

Sources cited

RACGP — Pharmacist prescribing without evidence: it’s the patients who suffer (6 July 2026). https://www.racgp.org.au/gp-news/media-releases/2026-media-releases/july-2026/pharmacist-prescribing-without-evidence-it-s-the-p
RACGP newsGP — Professional news. https://www1.racgp.org.au/newsgp/professional